Diabetes, Diabetes Mellitus, Type 2
Conditions
Brief summary
This trial is conducted in Europe. The aim of this trial is to assess the effect of NNC 90-1170 (liraglutide) on pulsatile insulin secretion and insulin secretion after a standard meal in subjects with type 2 diabetes.
Interventions
DRUGliraglutide
A single dose injected subcutaneously (under the skin)
DRUGplacebo
A single dose injected subcutaneously (under the skin)
Sponsors
Novo Nordisk A/S
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
30 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosed with type 2 diabetes, either newly diagnosed with at least two months of diet treatment, or in current OHA (oral hypoglycaemic agent) treatment with stable dose for at least six months * BMI (Body Mass Index) between 24 and 35 kg/m\^2 (both inclusive) * Fasting plasma glucose between 6 and 15 mmol/l (both inclusive) * Anti-GAD (glutamic acid decarboxylase) negative
Exclusion criteria
* Known or suspected allergy to trial product or related products * Receipt of any investigational drug within three months prior to this trial * Recurrent severe hypoglycaemia as judged by the investigator * Cardiac disease or any clinically significant abnormal ECG (electrocardiogram) * Use of any drug (except oral hypoglycaemic agents (OHAs)) which in the investigator's opinion could interfere * with the blood glucose level (i.e., insulin, systemic corticosteroids, thiazides) * Liver or renal disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Insulin secretory burst mass | — |
Secondary
| Measure | Time frame |
|---|---|
| Insulin secretory pulse mass, amplitude, frequency and regularity | — |
| Insulin secretion | — |
| Glucagon response | — |
| Gastric emptying rate | — |
| Adverse events | — |
Countries
Denmark
Outcome results
None listed